Company Overview
Company Type: Private Company
Website: nicoyalife.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 39.65
Total Rounds of Funding**:5
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Nicoya Lifesciences Inc. develops sensor products to get affinity, kinetics, and specificity for proteins, antibodies, DNA, RNA, enzymes, polymers, and small molecules. Its products include Alto, OpenSPR instruments, OpenSPR sensors, and OpenSPR software. It offers applications, such as antibodies, carbohydrates, lipids, nanoparticles, nucleic acids/aptamers, OpenSPR for education, proteins, and small molecules. The company was incorporated in 2012 and is based in Kitchener, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Denomme, Ryan 
Co-Founder & CEO
Calvert, Colin 
Chief Financial Officer
Ward, Brian 
Vice President of Operations
Sudarsan, Arjun 
Chief Technical Officer
Kumaraswamy, Sriram 
Senior Vice President of Marketing & Product
Sterlina, Patrick 
Chief of Engineering


Primary Industry Classification
Electronic Equipment and Instruments


Primary Office Location
29 King St E  Unit B | Kitchener, ON | N2G 2K4 | Canada
Phone: 877-673-6777   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Medical Innovation Xchange
Nov-02-2022
Minority
-
Accelerator
Agilent Technologies, Inc. (NYSE:A)
Jan-14-2020
Minority
-
Series A
Export Development Canada
Jan-14-2020
Minority
-
Series A
Garage Capital
Jan-14-2020
Unknown
-
Series A
Whitecap Venture Partners
Jan-14-2020
Minority
-
Series A

Prior Investors
Accelerator Centre, Ripple Ventures, Velocity


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
LSK Technologies Inc.
LSK Technologies Inc. develops and provides PLUM, an analyzer for testing infectious diseases, such as COVID-19. The company’s product detects viral RNA, proteins, and an immune response for COVID-19 and other diseases; and analyzes commercial assays in microplate and gel formats. It is also used for conducting environmental monitoring tests. The company serves medical professionals and scientists. LSK Technologies Inc. was incorporated in 2020 and is based in Toronto, Canada. As of May 2, 2022, LSK Technologies Inc. operates as a subsidiary of Nicoya Lifesciences Inc.

United States and Canada
Health Care Equipment
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-02-2022
-
Private Placement
Target
Nicoya Lifesciences Inc.
Medical Innovation Xchange

0.08
May-02-2022
May-02-2022
Merger/Acquisition
Buyer
LSK Technologies Inc.
Nicoya Lifesciences Inc.
Y Combinator
-
Jan-14-2020
Dec-16-2021
Private Placement
Target
Nicoya Lifesciences Inc.
MaRs Discovery District, Investment Arm,BDC Capital Inc.,Whitecap Venture Partners,Garage Capital,Agilent Technologies, Inc. (NYSE:A),Export Development Canada Buyer Funds:MaRS Investment Accelerator Fund

23.48
May-03-2019
-
Private Placement
Target
Nicoya Lifesciences Inc.
BDC Capital Inc.

3.91
Jan-30-2018
Jan-30-2018
Private Placement
Target
Nicoya Lifesciences Inc.
MaRs Discovery District, Investment Arm,Ripple Ventures,BDC Capital Inc.,Innovation Grade Ventures Buyer Funds:MaRS Investment Accelerator Fund

1.62
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-25-2023
Company Conference Presentations
Nicoya Lifesciences Inc. Presents at 2023 Bloom Burton & Co. Healthcare Investor Conference, Apr-25-2023 09:30 AM
Mar-21-2023
Company Conference Presentations
Nicoya Lifesciences Inc. Presents at Festival of Biologics World Antibody Congress USA, Mar-20-2023 05:00 PM
Nov-02-2022
Private Placements
Nicoya Lifesciences Inc. announced that it expects to receive $0.075 million in funding from Medical Innovation Xchange
Oct-12-2022
Client Announcements
INOVIQ Limited Signs Contract Research Agreement with Nicoya Lifesciences Inc
May-02-2022
Company Conference Presentations
Nicoya Lifesciences Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, May-02-2022 03:00 PM


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Denomme, Ryan 
Co-Founder & CEO
877-673-6777
-

Calvert, Colin 
Chief Financial Officer
877-673-6777
-

Ward, Brian 
Vice President of Operations
877-673-6777
-

Sudarsan, Arjun 
Chief Technical Officer
877-673-6777
-

Kumaraswamy, Sriram 
Senior Vice President of Marketing & Product
877-673-6777
-

Sterlina, Patrick 
Chief of Engineering
877-673-6777
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
